PMV PHARMACEUTICALS, INC. (PMVP) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -79.67M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 64.04M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-79.67M | (m) | (m) | $64.04M | (m) | (m) |
| 2026-03-31 | $-83.66M | (m) | (m) | $67.77M | (m) | (m) |
| 2025-12-31 | $-86.21M | (m) | (m) | $69.88M | (m) | (m) |
| 2025-09-30 | $-92.13M | (m) | (m) | $67.82M | (m) | (m) |
| 2025-06-30 | $-91.50M | (m) | (m) | $66.56M | (m) | (m) |
| 2025-03-31 | $-88.79M | (m) | (m) | $62.78M | (m) | (m) |
| 2024-12-31 | $-85.45M | (m) | (m) | $58.53M | (m) | (m) |
| 2024-09-30 | $-79.18M | (m) | (m) | $58.14M | (m) | (m) |
| 2024-06-30 | $-76.92M | (m) | (m) | $54.78M | (m) | (m) |
| 2024-03-31 | $-76.87M | (m) | (m) | $54.00M | (m) | (m) |
| 2023-12-31 | $-80.13M | (m) | (m) | $55.88M | (m) | (m) |
| 2023-09-30 | $-82.39M | (m) | (m) | $57.53M | (m) | (m) |
| 2023-06-30 | $-82.14M | (m) | (m) | $57.61M | (m) | (m) |
| 2023-03-31 | $-79.90M | (m) | (m) | $55.23M | (m) | (m) |
| 2022-12-31 | $-77.04M | (m) | (m) | $51.99M | (m) | (m) |
| 2022-09-30 | $-74.35M | (m) | (m) | $49.13M | (m) | (m) |
| 2022-06-30 | $-70.07M | (m) | (m) | $44.63M | (m) | (m) |
| 2022-03-31 | $-65.24M | (m) | (m) | $40.83M | (m) | (m) |
| 2021-12-31 | $-58.29M | (m) | (m) | $36.49M | (m) | (m) |
| 2021-09-30 | $-50.32M | (m) | (m) | $30.51M | (m) | (m) |
| 2021-06-30 | $-43.93M | (m) | (m) | $27.34M | (m) | (m) |
| 2021-03-31 | $-38.96M | (m) | (m) | $25.48M | (m) | (m) |
| 2020-12-31 | $-34.94M | (m) | (m) | $23.93M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-26.64M | (m) | (m) | $20.76M | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-18.89M | (m) | (m) | $13.85M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |